Andrew received his B.Sc. in Materials Science and Engineering (2014) and M.Sc. in Biomedical Engineering (2015) from Carnegie Mellon University. He is currently a Ph.D. student in Adam Feinberg’s Regenerative Biomaterials and Therapeutics Group. The goal of Andrew’s research is to vastly improve the resolution and vascularization of 3D bioprinted tissues to engineer the next generation of living tissues such as cardiac muscle for heart attack patients. The 3D bioprinting technology developed in the Feinberg lab was spun out into the CMU-based startup FluidForm which turns any FDM 3D printer into a world-class bioprinter.